FRACTURE INCIDENCE AND ECONOMIC BURDEN OF FEMALE PATIENTS WITH OSTEOPOROSIS AT VERY HIGH RISK OF FRACTURE IN CHINA
Author(s)
wenxuan jiang, master, Pinan Chen, PhD, Shitong Xie, PhD, Jing Wu, PhD;
Tianjin University, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin, China
Tianjin University, School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin, China
OBJECTIVES: To investigate the real-world fracture incidence and economic burden of female patients with Osteoporosis at very high risk of fracture (OPVHRF) in China.
METHODS: Data were obtained from Tianjin Healthcare Big Data Super Platform (2019-2023). Female patients aged ≥50 years with diagnosis of Osteoporosis (OP) during the selection period (June 2020 to June 2021) were identified. The OPVHRF patients’ index date was the earliest OPVHRF diagnosis date, with a 12-month baseline and ≥2 years of follow-up until study end, death, or loss to follow-up. OP patients who didn’t have any diagnosis of OPVHRF during the selection period were classified as the control group. The fracture incidence, distribution of fracture counts, healthcare resource utilization and direct medical costs were assessed.
RESULTS: 44,493 OP patients were identified, among whom 11,433 (25.7%) were diagnosed with OPVHRF. The mean (SD) age was 66.6 (9.83) years in OPVHRF patients and 65.0 (9.18) years in the control group. In first year of follow-up, the fracture incidence among OPVHRF patients was 136.11 per 100 person years while the control group was 1.44 per 100 person years (P < 0.01). The proportion of ≥4 fracture counts of OPVHRF patients was significantly higher than control group (10.7% vs 5.0%, P < 0.01). The annual all-cause hospitalization visits, outpatient visits and total direct medical costs (mean±SD) between OPVHRF patients and control group were 0.54 ± 0.97 vs 0.25 ± 0.77 (P < 0.01), 10.10 ± 23.26 vs 8.49 ± 19.68 (P < 0.01) and ¥22,206.13 ± 51,782.18 vs ¥10,597.87 ± 29,237.43 (P < 0.01), respectively.
CONCLUSIONS: More than one-quarter of OP patients were identified as OPVHRF associated with much higher fracture incidence, multiple fracture rate and economic burden in China, leading to substantial clinical and economic burden to the Chinese health care system. Enhanced attention and targeted management are needed for these patients.
METHODS: Data were obtained from Tianjin Healthcare Big Data Super Platform (2019-2023). Female patients aged ≥50 years with diagnosis of Osteoporosis (OP) during the selection period (June 2020 to June 2021) were identified. The OPVHRF patients’ index date was the earliest OPVHRF diagnosis date, with a 12-month baseline and ≥2 years of follow-up until study end, death, or loss to follow-up. OP patients who didn’t have any diagnosis of OPVHRF during the selection period were classified as the control group. The fracture incidence, distribution of fracture counts, healthcare resource utilization and direct medical costs were assessed.
RESULTS: 44,493 OP patients were identified, among whom 11,433 (25.7%) were diagnosed with OPVHRF. The mean (SD) age was 66.6 (9.83) years in OPVHRF patients and 65.0 (9.18) years in the control group. In first year of follow-up, the fracture incidence among OPVHRF patients was 136.11 per 100 person years while the control group was 1.44 per 100 person years (P < 0.01). The proportion of ≥4 fracture counts of OPVHRF patients was significantly higher than control group (10.7% vs 5.0%, P < 0.01). The annual all-cause hospitalization visits, outpatient visits and total direct medical costs (mean±SD) between OPVHRF patients and control group were 0.54 ± 0.97 vs 0.25 ± 0.77 (P < 0.01), 10.10 ± 23.26 vs 8.49 ± 19.68 (P < 0.01) and ¥22,206.13 ± 51,782.18 vs ¥10,597.87 ± 29,237.43 (P < 0.01), respectively.
CONCLUSIONS: More than one-quarter of OP patients were identified as OPVHRF associated with much higher fracture incidence, multiple fracture rate and economic burden in China, leading to substantial clinical and economic burden to the Chinese health care system. Enhanced attention and targeted management are needed for these patients.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
RWD11
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)